PRIMARY STUDY
Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study
Key Findings: For subjects on methadone therapy for opioid use disorder 10 mg THC provided greater relief than 20 mg THC by for self-reported pain sensitivity measures. There was no substantial evidence of abuse potential, and inconsistent dose-dependent cognitive adverse effects.
Type of Study: Clinical Trial
Study Sample Size: 25
Study Result: Positive
Research Location(s): United States
Year of Pub: 2023
Cannabinoids Studied: Tetrahydrocannabinol (THC), Pharma THC
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype I
Receptors Studied: Opioid Receptor Nociceptin
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile, Synergistic Dose,
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (Pharma THC) 0 
Dosage Form: dronabinol
Dosing Regimen: THC 10 or 20 mg or placebo, during three separate 5-h test sessions
Clinical Relevance: Delta-9-tetrahydrocannabinol (THC) may be udeful in pain relief among individuals receiving opioid agonist therapy for opioid use disorder.
Adverse Events: inconsistent dose-dependent cognitive adverse effects
Additional Notes: Parallel Dose Comparison
Citation: De Aquino JP, et al. Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study. Addict Biol. 2023; 28:e13317. doi: 10.1111/adb.13317
Authors: De Aquino JP, Meyerovich J, Xie CZ, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M
